semaglutide patent expiry date opens door to GLP-1 generics in Canada A Snapshot of the Semaglutide

Tirzepatide is the active ingredient that acts as a dual agonist of GLP-1 and GIP receptors and has been shown to help people lose significant amounts of body weight, with some studies reporting up to 22.5%* reduction in body weight

For this person, the potential to lose over 20% of their body weight with tirzepatide could be life-changing, making it the more compelling choice

Patients considering this transition should consult their provider about monitoring parameters, potential dose adjustments, and adverse event tracking to ensure continuity of care during any formulation change

We are located in Alexandria, Virginia and serve patients from all over the Mid-Atlantic including Washington DC, Alexandria, Baltimore, and Chevy Chase

But older adults also face greater risks from muscle loss